help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bowden, R. T.
Right arrow Articles by Moore, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowden, R. T.
Right arrow Articles by Moore, M. R.

Endocrinology, Vol 124, 2642-2644, Copyright © 1989 by Endocrine Society

ARTICLES

Growth stimulation of T47D human breast cancer cells by the anti- progestin RU486

RT Bowden, JR Hissom and MR Moore
Department of Biochemistry, Marshall University School of Medicine, Huntington, West Virginia 25704.

Our laboratory has previously reported that physiological levels of progestins stimulate growth of the human breast cancer cell line T47D. We have also determined that the antiprogestin RU486 inhibits this stimulation. Here we present the unexpected finding that RU486 alone also stimulates growth of these breast cancer cells. Thus, RU486 exhibits both antagonist and agonist-like activity, in a manner somewhat reminiscent of the antiestrogen tamoxifen. To our knowledge, this is the first report of stimulation of breast cancer growth by RU486.


This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
R. P. Carnevale, C. J. Proietti, M. Salatino, A. Urtreger, G. Peluffo, D. P. Edwards, V. Boonyaratanakornkit, E. H. Charreau, E. B. de Kier Joffe, R. Schillaci, et al.
Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways
Mol. Endocrinol., June 1, 2007; 21(6): 1335 - 1358.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Shatnawi, T. Tran, and M. Ratnam
R5020 and RU486 Act as Progesterone Receptor Agonists to Enhance Sp1/Sp4-Dependent Gene Transcription by an Indirect Mechanism
Mol. Endocrinol., March 1, 2007; 21(3): 635 - 650.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Skildum, E. Faivre, and C. A. Lange
Progesterone Receptors Induce Cell Cycle Progression via Activation of Mitogen-Activated Protein Kinases
Mol. Endocrinol., February 1, 2005; 19(2): 327 - 339.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
X. Qiu, X. Sun, A. Christow, B. Stabi, and K. Gemzell-Danielsson
The effect of mifepristone on the expression of insulin-like growth factor binding protein-1, prolactin and progesterone receptor mRNA and protein during the implantation phase in human endometrium
Mol. Hum. Reprod., November 1, 2002; 8(11): 998 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Zou, K. B. Marschke, K. E. Arnold, E. M. Berger, P. Fitzgerald, D. E. Mais, and E. A. Allegretto
Estrogen Receptor {beta} Activates the Human Retinoic Acid Receptor {alpha}-1 Promoter in Response to Tamoxifen and Other Estrogen Receptor Antagonists, but Not in Response to Estrogen
Mol. Endocrinol., March 1, 1999; 13(3): 418 - 430.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society